New trial! Jennifer Ligibel MD of Dana-Farber Cancer Institute & Kathryn Schmitz PhD of UPMC Hillman Cancer Center lead Alliance A222302 studying the feasibility of a telehealth exercise program for cancer patients with the goal of reducing fatigue and disability. https://bit.ly/DEFEND-trial #NCTN
Apply to the @swog.org Virtual Grant Writing Workshop!
Across 6 wks, dive into:
>Lectures on grantsmanship
>Peer-review sessions
>Guidance on spec aims and research strategy
>Access to biostats support
For all #SWOGonc members & investigators across the #NCTN
thehopefoundation.org/funding-oppo...
Now recruiting! Dr. Bradley McGregor of the Dana-Farber Cancer Institute leads Alliance A032201 (STRIKE) to see if adding the tivozanib to the standard treatment of immunotherapy after surgery helps patients with high-risk renal cell cancer. Learn more: https://bit.ly/Alliance-A032201 #NCTN
Trial Tuesday! Dr. Deepak Kilari from Medical College of Wisconsin is now enrolling Alliance A032302, the ASPIRE trial to see if adding chemo to hormone therapy improves survival in men with metastatic #prostatecancer. To learn more, visit http://bit.ly/AllianceA032302 #NCI #NCTN #NCORP
A blood test could help doctors decide which patients with advanced colon cancer should receive NSAIDs along with chemotherapy after surgery, according to new study on Alliance data in JAMA Oncology. JAMA Oncology
https://bit.ly/JAMA-NSAID #coloncancer #NCI #NCTN
We hosted our National Clinical Trials Network #NCTN Summit last week to gather our #clinicalresearch teams, celebrate accomplishments, and discuss the year ahead. Hosted by Dr. Anne Chiang with @drdawnhershman.bsky.social @columbiacancer.bsky.social as keynote speaker, the day was a great success!
Now recruiting! Dr. Brad McGregor of Dana-Farber Cancer Institute leads A032201 (STRIKE) to see if adding the anti-cancer drug tivozanib to the standard treatment of immunotherapy after surgery helps patients with high-risk renal cell cancer. Learn more: https://bit.ly/Alliance-A032201 #NCI #NCTN
"Cancer statistics, 2026: Charting a course for a national cancer research agenda," commentary by Dr. Primo Lara, Jr, & @drdawnhershman.bsky.social publ w the annual portrait of U.S. #cancer stats in CA: A Cancer Journal for Clinicians, just out! #NCTN #NCORP @eaonc.bsky.social @nrgonc.bsky.social
Now enrolling! Dr. Dean Shumway of the Mayo Clinic leads Alliance for Clinical Trials in Oncology A012301 (LoTam) comparing low-dose tamoxifen vs usual hormonal therapy for post-menopausal women with early-stage HER2-negative #breastcancer. Learn more: https://bit.ly/Alliance-A012301 #NCI #NCTN
A blood test could help doctors decide which patients with advanced colon cancer should receive NSAIDs along with chemotherapy after surgery, according to new study on CALGB/Alliance data published in JAMA Oncology. Learn more at https://bit.ly/JAMA-NSAID #coloncancer #NCI #NCTN
At the Alliance for Clinical Trials in Oncology, we share stories that highlight the progress and impact of cancer research. Click to see some of our recent media coverage. https://bit.ly/Media-2025 #NCI #NCTN
Dr. Anne Beaven of UNC Lineberger leads Alliance for Clinical Trials in Oncology A052101, a trial to see if older people with mantle cell lymphoma can receive fewer treatments of zanubrutinib while in remission. Learn more: https://bit.ly/Alliance-A052101 #MCL #NCI #NCTN
Sascha Tuchman, MD of UNC Lineberger leads Alliance for Clinical Trials in Oncology A062102, a trial comparing iberdomide maintenance therapy to disease monitoring to improve survival in patients with multiple #myeloma. To learn more, visit https://bit.ly/Alliance-A062102
#NCTN #CancerResearch
Just activated!
#NCTN S2433 trial is enrolling patients with locally advanced or metastatic #pancreatic ductal adenocarcinoma without KRAS or BRAF V600E mutations. Randomized to physician’s choice SOC w/wo panitumumab. #pancsm
PI: Rachael A. Safyan, MD @fredhutch.org
swog.org/clinical-tri...
Now enrolling! Dr. Dean Shumway of Mayo Clinic leads Alliance A012301 (LoTam) comparing low-dose tamoxifen vs usual hormonal therapy for post-menopausal women with early-stage HER2-negative #breastcancer. Learn more: https://bit.ly/Alliance-A012301 #NCI #NCTN #BCsm #ClinicalTrials
New trial! Jennifer Ligibel MD of Dana-Farber Cancer Institute and Kathryn Schmitz PhD of
UPMC Hillman lead Alliance A222302 studying the feasibility of a telehealth exercise program for cancer patients with the goal of reducing fatigue and disability. https://bit.ly/A222302 #NCI #NCTN
Over the past grant cycle, Alliance researchers enrolled 10,000 patients in clinical trials, supported 5,000 more in #NCTN studies, and published hundreds of manuscripts. This work shapes guidelines, informs FDA decisions, and improves lives. #CancerResearch #ClinicalTrials
Trial Tuesday! Deepak Kilari MD from Medical College of Wisconsin leads new Alliance for Clinical Trials in Oncology A032302, ASPIRE, to see if adding chemo to hormone therapy improves survival in men with metastatic #prostatecancer. To learn more, visit bit.ly/AllianceA032302. #NCI #NCTN #NCORP
Cristina Ferrone, MD, of Massachusetts General Hospital leads Alliance A021806 studying whether chemotherapy before and after surgery is better than just after surgery for pancreas cancer. Learn more: https://bit.ly/Alliance-A021806 #NCI #NCTN #pcam #PanCancer #PancSM #PancreaticCancerAwarenessMonth
Radiation oncologist Dean Shumway, MD, of Mayo Clinic leads Alliance for Clinical Trials in Oncology A012301 (LoTam) comparing low-dose tamoxifen to usual hormonal therapy in treating post-menopausal women with early-stage HER2 #breastcancer. More at https://bit.ly/Alliance-A012301 #NCI #NCTN #BCsm
Results from Alliance A091802 led by Dan Zanberg, MD, of @upmchillmancc.bsky.social published in The ASCO Post show a new type of immunotherapy called immune checkpoint inhibitors help people with aggressive #skincancer live longer. Read more: https://bit.ly/A091802 #NCI #NCTN
New trial! Bhavana Konda, MD, MPH, of The Ohio State University leads Alliance for Clinical Trials in Oncology A092204 exploring if using two targeted drugs can help slow tumor growth in people with adrenocortical carcinoma, a adrenal gland cancer. https://bit.ly/A092204-Konda #NCI #NCTN
Alliance for Clinical Trials in Oncology has launched six new clinical trials, exploring novel therapies and innovative approaches to cancer care. From testing new drugs to evaluating digital tools, these trials aim to improve outcomes & personalize treatment. https://bit.ly/NewTrials2025 #NCI #NCTN
It's a wrap on an exciting three-day meeting! THANK YOU to everyone participating in the 2025 Alliance Fall Group Meeting. Your remarkable efforts continue to advance cancer research. See you next spring - May 13-15! #AllianceFall25 #NCI #NCTN #NCORP #CancerResearch
Congratulations, Linda Bulone, RN (Queens Hospital Cancer Center) - 2025 recipient of the Alliance Research Integrity Service Excellence (CRP RISE) Award! #AllianceFall25 #NCI #NCTN #NCORP #OncologyResearch
Kudos to En Cheng, MD, PhD, of the Albert Einstein School of Medicine, for one of the Most Significant Alliance Manuscripts 2024-2025! "Plant-based Diet and Survival Among - Patients with Metastatic Colorectal Cancer" in JNCI #AllianceFall25 #NCI #NCTN #CALGB-80405 #SWOG-80405
Kudos to Jennifer Chan, MD, MPH, of Dana-Farber Cancer Institute, for one of the Most Significant Alliance Manuscripts 2024-2025! "Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors" in NEJM #AllianceFall25 #NCI #NCTN #CABINET #AllianceA021602
Kudos to Andrea Apolo, MD, of the National Cancer Institute, for one of the Most Significant Alliance Manuscripts 2024-2025! "Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma" in NEJM #AllianceFall25 #NCI #NCTN #AMBASSADOR #AllianceA031501
Hats off to our newly appointed Alliance Imaging Committee leaders! Andy Plodkowski, MD, and Heiko Schöder, MD, MBA, of Memorial Sloan Kettering Cancer Center, and Jeffrey Yap, PhD, of Huntsman Cancer Institute/University of Utah! #AllianceFall25 #NCI #NCTN #Imaging
Hats off to our newly appointed Alliance Radiation Oncology Committee leaders! Co-Chairs Daniel Trifiletti, MD, of Mayo Clinic in Florida. and Joseph Salama, MD, of Duke University Medical Center. #AllianceFall25 #NCI #NCTN #RadOnc
